Novel Drug Class: Ibrexafungerp, SCYNEXIS's lead compound, represents a first-in-class triterpenoid antifungal, providing a distinct mechanism of action crucial for combating drug-resistant fungal infections where existing treatments may fail.

Oral Formulation Advantage: The availability of an oral formulation for systemic fungal infections, particularly with potential future indications like invasive candidiasis, offers significant convenience for patients and healthcare providers, potentially enabling outpatient treatment where IV drugs are currently standard.

Broad-Spectrum Efficacy: Ibrexafungerp demonstrates broad-spectrum activity against a wide range of *Candida* species, including those resistant to commonly used azoles and echinocandins, addressing critical unmet needs in antifungal treatment.